Alveolar soft‐part sarcoma. A clinico‐pathologic study of half a century Academic Article Article uri icon


MeSH Major

  • Dependovirus
  • Factor VIII
  • Genetic Therapy
  • Genetic Variation
  • Genetic Vectors
  • Hemophilia A


  • In the period from 1923 to 1986 our pathologists examined pathologic material from 102 patients with alveolar soft-part sarcoma (ASPS). Followup clinical data is available for 91. Median followup is 7 years (range 1 month to 27 years). Local recurrence was only found if residual disease was left at the time of the original excision. Survival in those patients who presented without metastases was 77% at 2 years, 60% at 5 years, 38% at 10 years and 15% at 20 years (median 6 years). No survival advantage could be demonstrated for patients who received chemo and/or radiotherapy, although numbers are small and staging not uniform. An evaluation by electron microscopy and immunohistochemistry cannot confirm recent claims that ASPS is a muscle tumor. ASPS is an unusual neoplasm; the primary therapeutic option is aggressive surgical excision. Survival even with the development of metastases can be long.

publication date

  • January 1989



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E

PubMed ID

  • 2642727

Additional Document Info

start page

  • 1

end page

  • 13


  • 63


  • 1